Lexeo Therapeutics, Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, NY

Insiders trading volume in the past year

Lexeo Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Longitude Capital Partners IV, LLC 10%+ Owner $28.2M Nov 7, 2023
Omega Fund VI, L.P. 10%+ Owner $23.7M Nov 7, 2023
Invest A/S Lundbeckfond 10%+ Owner $20.2M Nov 7, 2023
Richard Nolan Townsend Chief Executive Officer, Director $580K -$1.29M -69% Mar 14, 2025
Kyle Rasbach Chief Financial Officer $335K Jan 17, 2025
Eric Adler Chief Medical Officer $301K -$10.4K -3.34% Feb 19, 2025
Paula H. Cholmondeley Director $214K +$105K +96% Nov 25, 2024
Paul McCormac Chief Technical Officer $191K Nov 7, 2023
Jenny Robertson Chief Legal Officer $166K -$9.27K -5.29% Mar 14, 2025
Jose Manuel Otero Chief Technical Officer $165K Mar 14, 2025
Tai Sandi See Chief Development Officer $156K -$6.56K -4.04% Mar 14, 2025
Steven Altschuler Director Jun 25, 2024
Reinaldo M. Diaz Director Jun 25, 2024
Mette Kirstine Agger Director Jun 25, 2024
Brenda Cooperstone Director Jun 25, 2024
Bernard Davitian Director Nov 2, 2023
Timothy Van Hauwermeiren Director Jul 5, 2024
Tolga Tanguler Director Nov 11, 2024

Recent Insider Transactions by Companies or Individuals for Lexeo Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.